Vaccines for conformational disorders

References

• Prusiner SB. Neurodegenerative diseases and prions. N Engl J. Med. 344(20), 1516–1526 (2001).
   Web of Science ®Google Scholar
• Wisniewski T, Sigurdsson EM, Aucouturier P, Frangione B. Conformation as a therapeuctic target in the prionoses and other neurodegenerative conditions. In: Molecular and Cellular Pathology in Prion Disease. Baker HF (Ed.), Humana Press, NJ, USA, 223–236 (2001).
   Google Scholar
• Mirra SS, Hart MN, Terry RD. Making the diagnosis of Alzheimer's disease. A primer for practicing pathologists. Arch. PathoL Lab. Med. 117(2), 132–144 (1993).
   Google Scholar
• Evans DA, Funkenstein H, Albert MS et al. Prevalence of Alzheimers disease in a community population of older persons — higher than previously reported. JAMA 262(18), 2551–2556 (1989).
   PubMed Web of Science ®Google Scholar
• Holman RC, Khan AS, Belay ED, Schonberger LB. Creutzfeldt-Jakob disease in the United States, 1979–1994: using national mortality data to assess the possible occurence of variant cases. Emerg. Infect. Dis. 2,333-337 (1996).
   Google Scholar
• Sadowski M, Kumar A, Wisniewski T Prion diseases. In: Neurology in Clinical Practice. Bradley WG (Ed.), Butterworth-Heinemann, Oxford, UK, 1613–1630 (2004).
   Google Scholar
• Scott MR, Will R, Ironside J et al. Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc. Natl Acad. Sci. USA 96(26), 15137–15142 (1999).
   Google Scholar
• •Provides convincing evidence for the transmission of BSE to humans.
   Google Scholar
• Britton TC, Al-Sarraj S, Shaw C, Campbell T, Collinge J. Sporadic Creutzfeldt—Jakob disease in a 16-year old in the UK. Lancet 346,1155 (1995).
   PubMedGoogle Scholar
• Hilton DA, Ghani AC, Conyers L et al. Accumulation of prion protein in tonsil and appendix: review of tissue samples. Br. Med. 1325(7365), 633–634 (2002).
   Google Scholar
• Spinney L. vCJD epidemic could be first of many, experts warn. Nature Med. 9(9) 1096 (2003).
   Web of Science ®Google Scholar
• Llewelyn CA, Hewitt PE, Knight RSG et aL Possible transmission of variant Creutzfeldt—Jakob disease by blood transfusion. Lancet 363,417–421 (2004).
   PubMed Web of Science ®Google Scholar
• ••Provides the first evidence for the potentialspread of vCJD by blood transfusion.
   Google Scholar
• DeArmond SJ. Alzheimer's disease and Creutzfeldt—Jakob disease: overlap of pathogenic mechanisms. CUIT: Opin. NeuroL 6(6), 872–881 (1993).
   Web of Science ®Google Scholar
• Wisniewski T, Golabek AA, Kida E, Wisniewski KE, Frangione B. Conformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis. Am. J. PathoL 147(2), 238–244 (1995).
   Google Scholar
• Wisniewski T, Frangione B. Amyloidosis in Alzheimer's disease. Lancet 346(8972), 441 (1995).
   PubMedGoogle Scholar
• Aucouturier P, Kascsak RJ, Frangione B, Wisniewski T. Biochemical and conformational variability of human prion strains in sporadic Creutzfeldt—Jakob disease. Neurosci. Lett. 274,33–36 (1999).
   PubMed Web of Science ®Google Scholar
• Soto C, Kascsak RJ, Saborio GP etal. Reversion of prion protein conformational changes by synthetic 3-sheet breaker peptides. Lancet 355,192–197 (2000).
   Google Scholar
• •Demonstrates the use of a novel '13-sheet breaker to inhibit prion replication.
   Google Scholar
• Selkoe DJ. The origins of Alzheimer's disease: A is for amyloid. JAMA 283(12), 1615–1617 (2000).
   PubMed Web of Science ®Google Scholar
• Ghiso J, Frangione B. Amyloidosis and Alzheimer's disease. Adv Drug Deily. Rev 54,1539–1551 (2002).
   PubMed Web of Science ®Google Scholar
• Wisniewski T, Ghiso J, Frangione B. Alzheimer's disease and soluble AB. NeurobioL Aging 15(2), 143–152 (1994).
   PubMed Web of Science ®Google Scholar
• DeArmond SJ, Kretzschmar H, Prusiner SB. Prion diseases. In: Greenfield.'s Neuropathology Graham DI, Lantos P (Eds), Arnold, London, UK, 273–324 (2002).
   Google Scholar
• DeArmond SJ, Prusiner SB. Etiology and pathogenesis of prion diseases. Am. J. PathoL 146(4), 785–811 (1995).
   Google Scholar
• Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 298 (5594), 789–791 (2002).
   PubMed Web of Science ®Google Scholar
• Lewis J, Dickson D, Lin WL et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293,1487 (2001).
   PubMed Web of Science ®Google Scholar
• •Demonstrates that amyloid deposition in a transgenic model expressing both human APP and tau, can promote neurofibrillary tangles.
   Google Scholar
• Ma JY, Wollmann R, Lindquist S. Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science 298(5599), 1781–1785 (2002).
   PubMed Web of Science ®Google Scholar
• Ma JY, Lindquist S. Wild type PrP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation. Proc. Natl Acad. Sci. USA 98(26), 14955–14960 (2001).
   Google Scholar
• DeArmond SJ, Prusiner SB. Prion protein transgenes and the neuropathology in prion diseases. Brain Path& 5 (1), 77–89 (1995).
   PubMed Web of Science ®Google Scholar
• Wisniewski HM, Bancher C, Barcikowska M, Wen GY, Currie J. Spectrum of morphological appearance of amyloid deposits in AD. Acta Neuropathol 78, 337–347 (1989).
   Google Scholar
• Wisniewski T, Castafio EM, Golabek AA, Vogel T, Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am. .1. Path& 145(5), 1030–1035 (1994).
   Google Scholar
• Sanan DA, Weisgraber KH, Russell SJ et al. Apolipoprotein E associates with 13 amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. I Clin. Invert. 94(2), 860–869 (1994).
   Google Scholar
• Ma J, Yee A, Brewer HB, Jr, Das S, Potter H. Amyloid-associated proteins al-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer (3-protein into filaments. Nature372(6501), 92–94 (1994).
   Google Scholar
• Johnson LV, Leitner WP Rivest AJ, Staples StaplesM, Radeke MJ, Anderson DH. The Alzheimer's AB-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc. Natl Acad. Sci. USA 99(18), 11830–11835 (2002).
   Google Scholar
• Boyett KW, DiCarlo G, Jantzen PT et al Increased fibrillar (3-amyloid in response to human Clq injections into hippocampus and cortex of APP+PS1 transgenic mice. Neurochem. Res. 28(1), 83–93 (2003).
   Google Scholar
• Wisniewski T, Lalowski M, Golabek AA, Vogel T, Frangione B. Is Alzheimer's disease an apolipoprotein E amyloidosis? Lancet 345(8955), 956–958 (1995).
   Google Scholar
• Wisniewski HM, Sadowski M, Jakubowska- Sadowska K, Tarnawski M, Wegiel J. Diffuse, lake-like amyloid-I3 deposits in the parvopyramidal layer of the presubiculum in Alzheimer's disease. I Neuropathol Exp. Neurol 57(7), 674–683 (1998).
   Google Scholar
• Telling GC, Haga T, Torchia M et al Interactions between wild type and mutant prion proteins modulate neurodegeneration transgenic mice. Genes Dev. 10(14), 1736–1750 (1996).
   Google Scholar
• Shibata M, Yamada S, Kumar S et al Clearance of Alzheimer's amyloid-I31_40 peptide from brain by LDL receptor-related protein-1 at the blood—brain barrier. .1. Clin. Invest. 106(12), 1489–1499 (2000).
   Google Scholar
• Gomez-Isla T, Growdon WB, McNamara MJ et al The impact of different presenilin 1 and presenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuronal loss in the familial Alzheimer's disease brain — evidence for other phenotype-modifying factors. Brain 122,1709–1719 (1999).
   PubMed Web of Science ®Google Scholar
• Westaway D, DeArmond SJ, Cayetanocanlas J etal. Degeneration of skeletal muscle, peripheral nerves and the central nervous system in transgenic mice overexpressing wild type prion proteins. Ce1176(1), 117–129 (1994).
   Google Scholar
• Prusiner SB, Scott MR, DeArmond SJ, Cohen FE. Prion protein biology. Cell 93, 337–348 (1998).
   PubMed Web of Science ®Google Scholar
• Jeffrey M, McGovern G, Martin S, Goodsir CM, Brown KL. Cellular and subcellular localisation of PrP in the lymphoreticular system of mice and sheep. Arch. Virol 145, 23–38 (2000).
   Google Scholar
• Schenk D. Opinion: amyloid-I3 immunotherapy for Alzheimer's disease: the end of the beginning. Nature Rev Neurosci. 3,824–828 (2002).
   PubMed Web of Science ®Google Scholar
• Schenk D, Barbour R, Dunn W et al. Immunization with amyloid-I3 attenuates Alzheimer's disease-like pathology in the PDAPP mice. Nature 400,173–177 (1999).
   PubMed Web of Science ®Google Scholar
• ••Provides the first evidence that vaccinationcan reduce the amyloid burden in model animals.
   Google Scholar
• Sigurdsson EM, Scholtzova H, Mehta P, Frangione B, Wisniewski T. Immunization with a nontoxicinonfibrillar amyloid-I3 homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice. Am. .1. Path& 159,439–447 (2001).
   Google Scholar
• •Demonstrates that nontoxic, nonfibrillogenic Ali peptide derivates, which are less likely to be associated with toxicity, can be used to reduce the amyloid burden in AD model mice.
   Google Scholar
• Morgan D, Diamond DM, Gottschall PE et al A13 peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408,982–985 (2001).
   Web of Science ®Google Scholar
• Janus C, Pearson J, McLaurin J et al AB peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nattilv 408,979–982 (2000).
   Google Scholar
• Hock C, Konietzko U, Streffer JR et al Antibodies against (3-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38(4), 547–554 (2003).
   Google Scholar
• Hock C, Konietzko U, Paspassotiropoulos A et al. Generation of antibodies specific for (3-amyloid by vaccination of patients with Alzheimer's disease. Nature Med. 8,1270–1276 (2003).
   Web of Science ®Google Scholar
• Bacskai BJ, Kajdasz ST, Christie RH etal. Imaging of amyloid-I3 deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nature Med. 7,369-372 (2001).
   Google Scholar
• Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer 13-amyloid by site-directed mAb. Proc. Natl Acad. Sci. USA 94(8), 4109–4112 (1997).
   Google Scholar
• DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A13 antibody alters CNS and plasma A13 clearance and decreases brain A13 burden in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 98(15), 8850–8855 (2001).
   Google Scholar
• Sigurdsson EM, Wisniewski T, Frangione B. A safer vaccine for Alzheimer's disease? Neurobiol Aging 23,1001–1008 (2002).
   Google Scholar
• Kensil CR, Wu JY, Soltysik S. Structural and immunological characterization of vaccine adjuvant QS-21. Pharm. Biotechnol 6,525–541 (1995).
   Google Scholar
• Kensil CR, Soltysik S, Wheeler DA, Wu JY. Structure—function studies on Qs-21 — a unique immunological adjuvant from Quillaja—Saponaria. Abstracts of Papers of the American Chemical Society210,87-AGFD (1995).
   Google Scholar
• Orgogozo JM, Gilman S, Dartigues JF et al Subacute meningoencephalitis in a subset of patients with AD after A13 42 immunization. Neurology61(1), 46–54 (2003).
   Google Scholar
• Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer's disease after immunization with amyloid-I3 peptide: a case report. Nature Med. 9(4), 448–452 (2003).
   Google Scholar
• Greenberg SM, Bacskai BJ, Hyman BT. Alzheimer's disease's double-edged vaccine. Nature Med. 9 (4), 389–390 (2003).
   PubMed Web of Science ®Google Scholar
• Dodart JC, Bales KR, Paul SM. Immunotherapy for Alzheimer's disease: will vaccination work? Trends Mol Med. 9(3), 85–87 (2003).
   Google Scholar
• Bard F, Cannon C, Barbour R etal. Peripherally administered antibodies against amyloid 13-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nature Med. 6(8), 916–919 (2000).
   Google Scholar
• Pfeifer M, Boncristiano S, Bondolfi L et al Cerebral hemorrhage after passive anti-A13 immunotherapy. Science 298 (5597), 1379 (2002).
   Google Scholar
• Wisniewski T, Sigurdsson EM. Immunization treatment approaches in Alzheimer and prion diseases. CUIT: Neurol. Neurosci. Rep. 2, 400–404 (1988).
   Google Scholar
• Jameson BA, Wolf H. The antigenic index: a novel algorithm for predicting antigenic determinants. Comput. AppL Biosci. 4(1), 181–186 (1988).
   PubMedGoogle Scholar
• Monsonego A, Zota V, Bar-Or A etal. Immunogenic aspects of amyloid 13-peptide: implications for pathogenesis and treatment of Alzheimer's disease. Clin. Immunol. 103(3), S132 (2002).
   Google Scholar
• Petkova AT, Ishii Y, Balbach JJ et al. A structural model for Alzheimer's (3-amyloid fibrils based on experimental constraints from solid state NMR. Proc. Natl Acad. Sci. USA 99(26), 1674–16747 (2002).
   Google Scholar
• Sigurdsson EM, Knudsen E, Asuni A et al. A modest immune reseponse is sufficient to enhance cognition in an AD model immunized with Ail derivatives. j Neurosci. (In Press).
   Google Scholar
• •Demonstrates that immunization with Ali derivates that have the major T-cell epitopes removed can lead to cognitive improvement in AD model animals.
   Google Scholar
• Knudsen E, Wisniewski T, Quartermain D et al Immunization with amyloid-I3 derivatives improves cognition while provoking a weak antibody response. Society for Neuroscience Meeting Program 133.10 (2004).
   Google Scholar
• Gupta RK, Rost BE. Aluminum compounds as vaccine adjuvants. In: Vaccine Adjuvants. O'Hagan DT (Ed.), Humana Press, NJ, USA 65–89 (2000).
   Google Scholar
• Gupta RK. Aluminum compounds as vaccine. Adv. Drug Del. Rev 32,155–172 (1998).
   PubMed Web of Science ®Google Scholar
• Brayden DJ, Templeton L, McClean S etal. Encapsulation in biodegradable microparticles enhances serum antibody response to parenterally-delivered 13-amyloid in mice. Vaccine 19(30), 4185–4193 (2001).
   Google Scholar
• Frenkel D, Balass M, Solomon B. N-terminal EFRH sequence of Alzheimer's 13-amyloid peptide represents the epitope of its anti-aggregating antibodies. Neuroimmunol. 88(1–2), 85–90 (1998).
   Google Scholar
• Lemere CA, Maron R, Selkoe DJ, Weiner HL. Nasal vaccination with (3-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol. 20(11), 705–711 (2001).
   Google Scholar
• Weiner HL, Lemere CA, Maron R et al. Nasal administration of amyloid-I3 peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol. 48, 567–579 (2000).
   Google Scholar
• Geling A, Steiner H, Willem M, Bally-Cuif L, Haass C. A y-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish. EMBO Rep. 3(7), 688–694 (2002).
   PubMed Web of Science ®Google Scholar
• Doerfler P, Shearman MS, Perlmutter RM. Presenilin-dependent y-secretase activity modulates thymocyte development. Proc. Natl Acad. Sci. USA 98(16), 9312–9317 (2001).
   Google Scholar
• Figueroa DJ, Morris JA, Ma L et al Presenilin-dependent y-secretase activity modulates neurite outgrowth. Neurobiol. Dis. 9(1), 49–60 (2002).
   PubMed Web of Science ®Google Scholar
• Hadland BK, Manley NR, Su DM et al y- secretase inhibitors repress thymocyte development. Proc. Natl Acad. Sci. USA 98(13), 7487–7491 (2001).
   Google Scholar
• Xu M, Lai MT, Huang Q et al. y-Secretase: characterization and implication for Alzheimer's disease therapy. Neurobiol. Aging23(6), 1023–1030 (2002).
   PubMed Web of Science ®Google Scholar
• Benveniste H, Einstein G, Kim KR, Hulette C, Johnson GA. Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. Proc. Natl Acad. Sci. USA 96, 14079–14084 (1999).
   PubMedGoogle Scholar
• Wadghiri YZ, Sigurdsson EM, Sadowski M et al. Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn. Reson. Med. 50(2), 293–302 (2003).
   Google Scholar
• •Provides the first in vivo images of amyloid deposits in model animals using Ali targeting ligands. This method may be used to follow the amyloid burden.
   Google Scholar
• DeKosky ST, Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science 302(5646), 830–834 (2003).
   PubMed Web of Science ®Google Scholar
• Aucouturier P, Carp RI, Carnaud C, Wisniewski T. Prion diseases and the immune system. Clin. Immunol. 96, 79–85 (2000).
   PubMed Web of Science ®Google Scholar
• Sigurdsson EM, Brown DR, Daniels M et al Vaccination delays the onset of prion disease in mice. Am. j PathoL 161, 13–17 (2002).
   PubMed Web of Science ®Google Scholar
• Sigurdsson EM, Sy MS, Li R etal. Anti-PrP antibodies for prophylaxis following prion exposure in mice. Neurosci. Lett. 336, 185–187 (2003).
   Google Scholar
• White AR, Enever P, Tayebl M et al Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422, 80–83 (2003).
   PubMed Web of Science ®Google Scholar
• •Demonstrates that passive immunization in prion model mice can prevent infection if given within 1 month of exposure, using large doses of anti-PrP antibodies.
   Google Scholar
• Belay ED, Gambetti P, Schonberger LB et al Creutzfeldt-Jakob disease in unusually young patients who consumed venison. Arch. Neurol. 58(10), 1673–1678 (2001).
   PubMedGoogle Scholar
• Raymond GJ, Bossers A, Raymond LD et al Evidence of a molecular barrier limiting susceptibility of humans, cattle and sheep to chronic wasting disease. EMBO 19(17), 4425–4430 (2000).
   PubMed Web of Science ®Google Scholar
• Wisniewski T, Sy MS, Sadowski M et al. Immunization approaches for the treatment of prion disease. Neurology60, A232 (2003).
   Google Scholar
• Sadowski M, Pankiewicz J, Scholtzova H et al. Targeting prion amyloid deposits in vivo using methoxy-X04. I Neuropath. Exp. Neurol. In Press (2004).
   Google Scholar
• •The first paper to in vivo image prion brain deposits using model mice.
   Google Scholar